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Objectives: Vein graft surveillance is of proven benefit in improving raft patency at least in the first year after arterial 
bypass urgery. The aim of this study was to look at the longer term outcome of a vein graft surveillance programme on 
graft patency. 
Methods: One hundred and twelve consecutive vein grafts in 106 patients were prospectively entered into a vein graft 
surveillance programme. The median (range) follow up was 34 (1-76) months. 
Results: There were 23 (21%) early (less than 1 month) failures and a further 15 grafts occluded uring follow up. The 
primary, primary assisted and secondary patencies at 4 years were 27%, 59% and 67% respectively. Thirty-eight grafts 
(34%) developed at least one stenosis at a median interval of 5 months after the operation. Eight (21%) of these stenoses 
occurred more than 12 months after surgery and would have been missed had surveillance been curtailed after 1 year. 
Conclusions: The benefits of graft surveillance xtend beyond one year and surveillance should therefore continue 
indefinitely. 
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Introduction 
Infrainguinal vein graft surveillance has been shown 
to be of benefit in several studies in the maintenance of 
1 12 patency of bypass grafts. - In a previous publication 
1 from our department we reviewed 112 consecutive 
vein grafts which were followed up in our vein graft 
surveillance programme for a median period of 14 
months. These vein grafts achieved aprimary patency 
of 40% at 42 months with primary assisted and 
secondary patencies of 65% and 69% respectively. 
Those patients who remain alive with patent grafts 
confinue to be followed up in our graft surveillance 
programme. This paper describes the longer term 
outcome of these grafts. 
Patients and Methods 
All infrainguinal vein bypass grafts performed 
between July 1988 and March 1992 were entered into 
our vein graft surveillance programme, a There were 
112 vein grafts in 106 patients. The median (range) age 
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of the patients was 75 (32-97). The male:female ratio 
was 68:38, there were 37 (35%) diabetics, 25 (24%) 
patients had a previous history of ischaemic heart 
disease, 33 (31%) patients admitted to continued 
smoking postoperatively and 43 (41%) patients were 
on aspirin postoperatively. 
The patients were examined in the vascular studies 
unit at intervals of 1, 3, 6, 9 and 12 months after their 
surgery then at 6 monthly intervals. A clinical assess- 
ment, measurement of resting and post-exercise ankle 
brachial pressure indices (ABPI), and Duplex scan of 
the graft took place at each visit. Since November 
1991, the graft and tibial vessels have also been 
routinely insonated with a colour-coded Duplex scan- 
ner (Diasonics Spectra, Diasonics Sonotron, Bedford, 
U.K.). Arteriography was performed if there was a 
serial fall in the resting ABPI > 0.1 or a post-exercise 
fall in ABPI > 0.1 or a segmental peak velocity ratio 
increase > 3 on Duplex. 
The initial treatment for any vein graft stenoses 
detected by surveillance was percutaneous trans- 
luminal angioplasty (PTA). Only one stenosis was 
treated primarily with open revision. This was for a 
long diffuse narrowing in the distal part of a below- 
knee popliteal in situ graft in a 70-year-old lady 
occurring 5months after surgery. The graft details are 
shown in Table 1. 
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Table 1. Graft details 
Indication 
Claudication 
Rest pain 
Tissue necrosis 
Graft type 
In situ 
Reversed 
Graft position 
Above-knee popliteal 
Below-knee popliteal 
Distal 
15 (13%) 
38 (34%) 
59 (53%) 
79 (71%) 
33 (29%) 
6 (5%) 
30 (27%) 
76 (68%) 
Data analysis 
Graft patency was assessed using the recommenda- 
tions of Rutherford 13 based On the suggestions of the 
Ad Hoc Committee on Reporting Standards of the 
Society for Vascular Surgery. 14 Primary patency was 
defined as uninterrupted patency after the initial 
surgery with no further procedure performed on the 
graft. Primary assisted patency requires that the graft 
remains patent but procedures uch as PTA can be 
performed to prevent subsequent graft failure. Secon- 
dary patency allows procedures to be performed to 
salvage an occluded graft. Patients who died during 
follow-up were censored to their last clinic attendance. 
Statistical analysis was performed using the statistical 
package SPSS for Windows (SPSS, Chertse3~ U.K.). 
Risk factors were compared using a Log Rank test 15 
for univariate analysis and a Cox proportional hazards 
model was used for multivariate analysis. 16 
Table 2. Stenosis details 
Site of stenosis Number 
Proximal anastomosis 3 
Distal anastomosis 12 
Proximal graft 6 
Mid graft 7 
Distal graft 10 
run-off disease was detected by the surveillance 
programme. 
The primary, primary assisted and secondary 
patency curves are shown in Fig. 1. The primary 
assisted patency was significantly better than the 
primary patency (p = 0.0001 Log Rank test). 
Smoking, diabetes mellitus, critical ischaemia, sin- 
gle vessel run-off and the ingestion of aspirin were not 
found to significantly affect primary, primary assisted 
or secondary patency using either a univariate Log 
Rank test or a Cox multivariate regression analysis. 
There was an increased mortality associated with 
diabetes (p -- 0.006), those not taking aspirin 
(p = 0.006), female gender (p = 0.03), and patients 
with single vessel run-off (p = 0.0001) using a Log 
Rank test. However, multivariate analysis showed 
diabetes not to be a significant factor but single vessel 
run-off (p -- 0.04), female gender (p = 0.04) and not 
taking aspirin (p = 0.004) were all still significant. 
Limb salvage was adversely affected in a univariate 
Log Rank analysis by diabetes (p = 0.02) but not in a 
multivariate analysis (p = 0.72). 
Results 
The 30 day mortality rate among the 106 patients 
undergoing surgery was 7%. Twenty-three (20%) of 
the grafts occluded during this period, four of these 
within the first 24 h. The median (range) follow up for 
all patients was 34 (1-76) months. Twenty-eight 
patients (26%) died during follow up with a 30% 
mortality rate at 4 years. Twenty-two limbs (20%) were 
lost with a 4 year limb salvage rate of 79%. Thirty- 
eight grafts (34%) developed at least one stenosis 
during follow up. The median (range) interval to 
development of a stenosis was 5 (2-46) months. Eight 
primary stenoses occurred over I year after the initial 
operation. These stenoses had not been present at 
earlier attendances at the surveillance clinic. 
Eight (7%) grafts required a n inflow procedure at a 
median (range) interval of 15 (1-38) months after 
surgery, and 12 (11%) grafts required PTA of a run-off 
vessel at a median (range) interval of 31 (2-61) months 
after surgery. The presence of significant inflow or 
Discussion 
There are no controlled trials of vein graft surveillance 
but there are several reports in the literature strongly 
suggesting a benefit of surveillance in maintaining 
vein graft patency. 1'2'4'5's'9"17'18 The recommended 
duration of a surveillance programme is uncertain. 
The time course of vein graft intimal hyperplasia in 
humans is not as well worked out as it is in animals. 
Angelini et al. showed that in experimental vein grafts 
in pigs, there was an initial rapid increase in medial 
and intimal smooth muscle cells in the first week, 
followed by a rapid increase in matrix production up 
to 4 weeks after surgery. ~9 After this time, there was a 
slow but gradual increase in smooth muscle cell 
numbers. Intimal hyperplasia in human vein grafts is 
thought o be maximal in the first 12-18 months after 
surgery. Some authors have reported very few 
3920 remediable problems after the first year"  and 
Taylor et al. reported no problems after the first year, 2~ 
recommending that surveillance should be curtailed 
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Fig. 1. Survival curves howing primar:~ primary assisted and secondary patencies. The numbers at risk are shown at the bottom. The 
percentage patency is shown for each curve at 12, 24, 36 and 48 months. The standard error is less than 10% at all points. 
after one year on the basis of cost. However, whilst 
intimal hyperplasia is relatively uncommon over 
12-18 months after bypass surger)~ atherosclerosis i  
quite common. 22 Atherosclerotic plaques can develop 
within the vein graft or in the native arteries of the 
patient. If there is significant disease in an inflow or 
run-off vessel  this can be picked up by vein graft 
surveillance. In our study, we have found eight first- 
time stenoses occurring over 1 year after bypass 
surgery. As these stenoses were not excised, we can 
not be sure of their histology but they may well have 
been atherosclerotic, In addition, we have also found 
eight inflow and 12" run-off problems requiring treat- 
ment. These problems in the native vessels were due 
to the progression of atherosclerosis. Five of the inflow 
and eight of the outflow problems were found over 12 
months after the initial operation. These problems 
would not have been found or treated had the patients 
not attended our graft surveillance clinic. Most steno- 
ses will go on to cause graft occlusion 1 and as the 
result of salvage procedures on occluded grafts are so 
poor, z3 we feel an aggressive policy on management  of 
graft stenoses is justified. Vein graft patency and limb 
salvage can be improved by an effective surveillance 
programme. This is beneficial to the patient and 
gratifying to the surgeon. Also in these cost-conscious 
times, it is important o prevent unnecessary amputa-  
tions, as the estimated cost to the community  of an 
amputat ion in 1992 was over £25 000. 8 Therefore, 
despite the relatively low number of stenoses found 
after 1 year, we currently continue graft surveillance 
for life at 6 monthly intervals after the first year. As the 
surveillance programme is already in place, the cost of 
seeing another patient at 6 monthly intervals is 
relatively inexpensive (the cost for a private patient is 
currently £124 for a single limb and £155 for a bilateral 
scan) compared to the cost of an amputation. 
It was disappointing to find that none of the risk 
factors associated with atherosclerosis seemed to have 
an effect on primary, pr imary assisted or secondary 
patencies in this cohort of patients. However, mortal- 
ity was significantly affected by the presence of single 
vessel run-off preoperativel:~ female gender and the 
use of aspirin. The presence of a single run-off vessel 
is an indication of severe lower limb atherosclerotic 
disease and is a reflection of atherosclerotic disease 
elsewhere, particularly the coronary arteries. Female 
gender appears to adversely affect mortal ity but this is 
related to the fact that women develop atherosclerotic 
disease at a greater age than men. The median (range) 
age for women in this group was 76 (37-85) whilst the 
median (range) age for men was 67 (37-97). Aspirin 
has been shown to be beneficial in preventing cardio- 
vascular morbidity and mortality 24 and even if it does 
not improve graft patency, it may allow the patient o 
live longer with his patent graft. This in itself should 
be reason enough to recommend its routine use. 
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